Press Coverage

Mauna Kea Technologies Announces Publication of a Meta-Analysis Demonstrating Cellvizio’s Significant Role in Detection of Esophageal Dysplasia and Cancer

13 July 2022

Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care, underscoring the key role of advanced imaging in slowing the rapid growth of esophageal cancer

Meta-analysis builds on recent data demonstrating that the use of Cellvizio is also associated with lower health services utilization and fewer overall endoscopy procedures

Latest News

Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround

Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround

Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 

Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio 

Mauna Kea Technologies Reports First Half 2025 Revenue 

Mauna Kea Technologies Reports First Half 2025 Revenue 

No results found.